Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

791
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
791
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

293
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
293
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.0K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.0K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

318
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
318
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

71
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
71

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osteoporosis and fragility fracture burden in Asia Pacific: Key findings from the APCO-IOF Asia Pacific Regional Audit.

Osteoporosis and sarcopenia·2026
Same author

Severe Short Stature Secondary to Nutritional Vitamin D Deficiency During COVID-19 Pandemic.

Indian journal of pediatrics·2026
Same author

Regional data, global lessons: what the Asia-Pacific osteoporosis audit teaches the world.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Delayed diagnosis of juvenile hemochromatosis due to missed ferritin testing in a case of hypogonadotropic hypogonadism.

JCEM case reports·2026
Same author

Magnitude and Determinants of Weight Loss Response to GLP-1/GIP Receptor Agonists in India: A Real-World Time-to-Event Analysis.

Indian journal of endocrinology and metabolism·2026
Same author

MASLD as a crucial component in the pathogenesis, evaluation and management of type 2 diabetes in Asian Indians.

Diabetes & metabolic syndrome·2026

Related Experiment Video

Updated: Mar 3, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.5K

Levosulpiride and Serum Prolactin Levels.

Mohammad Shafi Kuchay1, Ambrish Mithal1

  • 1Division of Endocrinology and Diabetes, Medanta - The Medicity, Gurgaon, Haryana, India.

Indian Journal of Endocrinology and Metabolism
|May 2, 2017
PubMed
Summary

Levosulpiride, used for dyspepsia, can cause high prolactin levels by blocking dopamine D2 receptors. This drug-induced hyperprolactinemia can mimic pituitary tumors, necessitating careful patient history.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Gastroenterology

Background:

  • Levosulpiride, the levorotatory enantiomer of sulpiride, is prescribed for various dyspeptic syndromes.
  • Its therapeutic effects stem from blocking enteric inhibitory dopaminergic type 2 (D2) receptors, enhancing gastrointestinal motility.
  • Central D2 receptor antagonism by levosulpiride can lead to both therapeutic benefits and adverse effects, notably hyperprolactinemia.

Purpose of the Study:

  • To investigate the impact of levosulpiride on serum prolactin levels.
  • To highlight the potential for levosulpiride-induced hyperprolactinemia to be misdiagnosed as pituitary tumors.
  • To emphasize the importance of drug history in diagnosing elevated prolactin.

Main Methods:

  • Review of levosulpiride's mechanism of action.
Keywords:
Galactorrhoeahyperprolactinemialevosulpiride

More Related Videos

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

15.9K
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

8.0K

Related Experiment Videos

Last Updated: Mar 3, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.5K
Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

15.9K
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

8.0K
  • Analysis of clinical manifestations of levosulpiride-induced hyperprolactinemia.
  • Comparison of drug-induced hyperprolactinemia with pituitary tumor-related hyperprolactinemia.

    • Main Results:

    • Levosulpiride significantly elevates serum prolactin levels in a notable number of patients.
    • Elevated prolactin levels (> 200 ng/mL) can occur, challenging traditional diagnostic assumptions of pituitary tumors.
    • Clinical manifestations include menstrual abnormalities and galactorrhea in females.

    Conclusions:

    • Levosulpiride is a frequent cause of significant hyperprolactinemia.
    • A thorough drug history is crucial for accurate diagnosis in patients with elevated prolactin.
    • This can prevent unnecessary investigations, such as brain imaging, for suspected pituitary tumors.